Remepy Publishes New Evidence Showing its Hybrid Drug, Hybridopa™, Effect on Structural Connectivity in the Brain of Parkinson's Patients Associated with Improved Clinical Outcome

Remepy Publishes New Evidence Showing its Hybrid Drug, Hybridopa™, Effect on Structural Connectivity in the Brain of Parkinson's Patients Associated with Improved Clinical Outcome

New npj Parkinson's Disease publication, building on the previously reported Hybridopa™ Phase IIa results, demonstrates for the first time, that behaviourally driven brain plasticity likely enhances the efficacy of dopaminergic treatment and provides both clinical and neurobiological benefitsThese findings further…